MedTrace Logo

Phase 1 Single Dose Study of ALXN1101 in Healthy Volunteers

NCT01894165 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2019-03-19

No results posted yet for this study

Summary

Phase 1 single dose study of ALXN1101 in healthy volunteers.

Conditions

  • Molybdenum Cofactor Deficiency (MoCD)
  • Rare Autosomal Recessive Disorder
  • Deficiency of Activity of Molybdenum-dependent Enzymes (Sulfite Oxidase [SOX], Xanthine Dehydrogenase, and Aldehyde Oxidase)

Interventions

DRUG

ALXN1101

Randomized to receive a single dose of ALXN1101 or placebo as per assigned cohort dose level.

DRUG

Placebo

Randomized to receive a single dose of ALXN1101 or placebo as per assigned cohort dose level.

Sponsors & Collaborators

  • Origin Biosciences

    lead INDUSTRY

Principal Investigators

  • Ronald Goldwater, MD · Parexel Baltimore Early Phase Clinical Unit

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2013-09-30
Completion
2013-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01894165 on ClinicalTrials.gov